Cabaletta Bio Q1 2023: R&D spend $12.4M; CABA-201 IND cleared, Fast Track granted

Cabaletta Bio, Inc.

2023-Q1 EPS reported -$0.45

R&D expenses $12.4M (Q1 2023) vs $9.2M (Q1 2022); G&A $4.5M vs $3.8M.
Cash and equivalents $93.8M as of March 31, 2023; runway into Q1 2025.
FDA cleared IND for CABA-201 Phase 1/2 trial in lupus nephritis and SLE; Fast Track Designation granted.
Trial to enroll 6 LN and 6 SLE patients at 1.0x10^6 cells/kg; three-month efficacy data expected H1 2024.
Preclinical and updated DSG3-CAART data to be presented at ASGCT 26th Annual Meeting May 16-20.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cabaletta Bio, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

310 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-141371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.